Today: 7 February 2026
Subscribe
Browse Category

Healthcare News News 17 November 2025 - 31 December 2025

Eli Lilly stock dips after hours as Jardiance, Mounjaro price-cut headlines land into 2026

Eli Lilly stock dips after hours as Jardiance, Mounjaro price-cut headlines land into 2026

NEW YORK, December 31, 2025, 17:16 ET — After-hours Eli Lilly and Co (LLY) shares slipped in after-hours trading on Wednesday. The stock was down about 0.5% at $1,074.68, after trading between $1,074.39 and $1,083.25 during the day on roughly 1.5 million shares. Drug pricing has moved back to the center of the investment case for large-cap pharmaceuticals as Washington pushes for lower costs and companies adjust prices in overseas growth markets. For Lilly, price assumptions matter because investors have priced in years of strong growth from its GLP‑1 franchise, a hormone-based drug class used for diabetes and weight loss.
31 December 2025
····
Vanda Pharma stock jumps premarket after FDA approves Nereus, first new motion-sickness vomiting drug in decades

Vanda Pharma stock jumps premarket after FDA approves Nereus, first new motion-sickness vomiting drug in decades

NEW YORK, December 31, 2025, 04:27 ET — Premarket Vanda Pharmaceuticals’ shares surged about 18% in premarket trading on Wednesday after the U.S. Food and Drug Administration approved its motion-sickness vomiting drug, Nereus (tradipitant). StockAnalysis+1 The approval matters now because Vanda is moving from a long-running regulatory story to a commercial one, with investors shifting quickly to questions of launch execution, insurance coverage and pricing. The company said it expects to launch Nereus in the coming months. Reuters+1 It also gives Vanda a fresh catalyst heading into year-end trading, when extended-hours moves can be amplified by thinner liquidity. Shares closed
31 December 2025
····
SELLAS Life Sciences (SLS) Stock Update: ASH 2025 Data, REGAL Trial Countdown, Analyst Targets, and Key Risks (Dec. 23, 2025)

SELLAS Life Sciences (SLS) Stock Update: ASH 2025 Data, REGAL Trial Countdown, Analyst Targets, and Key Risks (Dec. 23, 2025)

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) is closing out 2025 on a familiar biotech cocktail: fresh clinical data, a major late-stage catalyst approaching, and market activity that suggests traders are positioning for volatility. As of 12:22 UTC on Tuesday, Dec. 23, 2025, SLS stock traded around $2.64, according to market data. In the prior session, the stock closed around $2.64 after moving sharply higher on heavy volume (roughly 8.9 million shares)—a notable burst for a small-cap biotech. Investing.com So what’s behind the renewed attention? In short: SELLAS just presented updated Phase 2 AML data for SLS009 at ASH 2025,
23 December 2025
····
Moderna Stock (MRNA) News, Forecasts and Analysis: CEPI Bird Flu Funding, FDA Scrutiny and the 2026 Outlook (Dec. 20, 2025)

Moderna Stock (MRNA) News, Forecasts and Analysis: CEPI Bird Flu Funding, FDA Scrutiny and the 2026 Outlook (Dec. 20, 2025)

December 20, 2025 — Moderna, Inc. (NASDAQ: MRNA) is ending the year in classic Moderna fashion: a tug-of-war between near-term uncertainty (COVID policy and demand) and long-term optionality (a pipeline that still wants to be the sequel to the pandemic-era blockbuster). The stock last traded around $33.80, up roughly 9% from the prior close, with a market cap near $13 billion and a 52-week range roughly $22–$49. Investing.com That jump comes as investors digest a fresh burst of pandemic-preparedness funding tied to Moderna’s H5 bird flu program—while, at the same time, headlines swirl around potential FDA actions on COVID-19 vaccine
20 December 2025
·····
GSK plc (GSK) news: FDA approves twice‑yearly asthma biologic Exdensur on Dec. 17, 2025

GSK plc (GSK) news: FDA approves twice‑yearly asthma biologic Exdensur on Dec. 17, 2025

GSK plc (GSK) announced today that the FDA approved Exdensur (depemokimab‑ulaa) for severe eosinophilic asthma in patients 12+. Here’s what it means for GSK’s respiratory pipeline, competition, and shareholders on 17.12.2025. GSK plc (LSE/NYSE: GSK) is in the spotlight on Wednesday, 17 December 2025, after the company confirmed US FDA approval for Exdensur (depemokimab‑ulaa)—a new twice‑yearly biologic for severe asthma—while also releasing its latest share buyback update through a regulatory filing. Investegate+1 Below is a full, reader-friendly rundown of all current GSK news items dated 17.12.2025, plus what they signal for patients, clinicians, and investors. Today’s GSK headlines (17.12.2025) 1)
17 December 2025
····
Eli Lilly Stock (LLY) This Week: Retatrutide Breakthrough, EU Mounjaro Expansion and Orforglipron Fast‑Track Talk — Week Ahead Outlook (Updated Dec. 12, 2025)

Eli Lilly Stock (LLY) This Week: Retatrutide Breakthrough, EU Mounjaro Expansion and Orforglipron Fast‑Track Talk — Week Ahead Outlook (Updated Dec. 12, 2025)

Updated: December 12, 2025Company: Eli Lilly and Company (NYSE: LLY)Stock price (last close):$1,027.51 MarketWatch Eli Lilly stock closed the week at $1,027.51 after a late-week rally, outperforming a softer broader market session on Friday. MarketWatch The catalyst mix was familiar—but still powerful: blockbuster momentum in obesity/diabetes, fresh late-stage data that raises the bar for next-generation weight loss drugs, and a steady stream of regulatory and access headlines that keep Lilly’s pipeline and pricing strategy in the spotlight. This week’s narrative was dominated by three themes investors will keep debating into the week ahead: (1) how big retatrutide can become—and whether
13 December 2025
····
Immunovant (IMVT) Stock Jumps After $550 Million Share Offering as Graves’ Disease Launch Comes Into Focus

Immunovant (IMVT) Stock Jumps After $550 Million Share Offering as Graves’ Disease Launch Comes Into Focus

NEW YORK – December 11, 2025 – Shares of Immunovant, Inc. (NASDAQ: IMVT) were sharply in focus on Thursday after the clinical‑stage immunology company announced a $550 million common stock financing designed to fund development and a potential commercial launch of its lead FcRn inhibitor, IMVT‑1402, in Graves’ disease.Immunovant, Inc.+1 By late afternoon, Immunovant stock was trading around $25.75, up roughly 9% on the day, with an intraday range between $22.03 and $25.87, giving the company a market value of about $4 billion.Stock Titan That upbeat finish came despite an initial sell‑off; one early report noted shares dropped around 7%
11 December 2025
·····
Therapeutics (KYMR) Stock Rockets on KT‑621 Eczema Breakthrough, Then Pauses After $500M Share Offering – 9 December 2025 Update

Therapeutics (KYMR) Stock Rockets on KT‑621 Eczema Breakthrough, Then Pauses After $500M Share Offering – 9 December 2025 Update

Updated: December 9, 2025 Kymera Therapeutics’ stock has just done the biotech equivalent of a backflip: a ~40–50% one‑day surge on Monday after stunning eczema trial data, followed almost immediately by a cool‑down triggered by a $500 million stock offering and a wave of fresh analyst price‑target hikes.GlobeNewswire+3Investing.com+3Investing.com+3 This is the kind of setup that gets both momentum traders and long‑term biotech nerds leaning in. Where KYMR Stock Stands Today The immediate driver: KT‑621, Kymera’s oral STAT6 degrader, produced dupilumab‑like efficacy in atopic dermatitis (eczema) with clean safety in a small Phase 1b trial — and the Street went into
9 December 2025
·····
AbbVie (ABBV) Stock on November 29, 2025: Skyrizi’s Canada Win, Big-Money Flows and a Hot Valuation Debate

AbbVie (ABBV) Stock on November 29, 2025: Skyrizi’s Canada Win, Big-Money Flows and a Hot Valuation Debate

Published: November 29, 2025 AbbVie Inc. (NYSE: ABBV) heads into the final stretch of 2025 trading just below its record highs, after a powerful rally driven by immunology blockbuster drugs Skyrizi and Rinvoq. The stock closed at $227.70 on Friday, November 28, up 0.02% on the day and sitting within a 52‑week range of roughly $164 to $245. StockAnalysis+1 Year to date, AbbVie shares have climbed about 31–32%, and delivered roughly 38% over the past twelve months, easily outpacing the broader market. Simply Wall St+1 Today’s news flow (November 29, 2025) gives investors plenty to chew on: Below is a
29 November 2025
·····
GSK News Today (26 November 2025): Medicare Slashes Prices on Trelegy, Berenberg Lifts Target, and Buybacks Signal Confidence

GSK News Today (26 November 2025): Medicare Slashes Prices on Trelegy, Berenberg Lifts Target, and Buybacks Signal Confidence

GSK plc (LSE/NYSE: GSK) is in the spotlight today as U.S. Medicare unveils steep price cuts on key respiratory drugs, analysts lift their price targets, and regulators publish fresh details on the company’s ongoing share buyback programme. Here’s a complete, investor-focused look at what’s moving GSK right now. 1. Medicare’s New Drug Prices Hit GSK’s Trelegy and Breo Ellipta The biggest GSK headline today comes from Washington: Medicare has released the second round of negotiated prices for 15 of its costliest prescription medicines, with two GSK respiratory products on the list. Newsweek+3Reuters+3pharmaphorum+3 Key details: These new prices are scheduled to
26 November 2025
···
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk Slashes Wegovy and Ozempic Cash Prices to $349, Launches $199 Intro Deals as GLP‑1 Price War Escalates

Published November 17, 2025 Novo Nordisk moved aggressively today to cut out‑of‑pocket costs for its blockbuster GLP‑1 drugs Wegovy and Ozempic, unveiling new self‑pay prices and limited‑time offers that it says will reach tens of thousands of U.S. pharmacies and telehealth partners. The changes come just days after the Trump administration struck landmark pricing agreements with Novo Nordisk and Eli Lilly that will extend Medicare and Medicaid coverage to obesity drugs for the first time and launch a government-run discount pharmacy site, TrumpRx, in early 2026. The White House+2Reuters+2 At the same time, telehealth and discount platforms including GoodRx and
17 November 2025
··
Tonix Pharmaceuticals (TNXP) Jumps as TONMYA, First New Fibromyalgia Drug in 15 Years, Hits U.S. Pharmacies – November 17, 2025

Tonix Pharmaceuticals (TNXP) Jumps as TONMYA, First New Fibromyalgia Drug in 15 Years, Hits U.S. Pharmacies – November 17, 2025

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) moved sharply higher today after the company confirmed that TONMYA™ (cyclobenzaprine HCl sublingual tablets), its newly approved fibromyalgia treatment, is now commercially available by prescription across the United States.GlobeNewswire+1 TONMYA Officially Launches in the U.S. Tonix announced at 7:00 a.m. EST that TONMYA is available for pharmacy ordering nationwide and can now be prescribed for adults with fibromyalgia.GlobeNewswire The drug is: TONMYA became the first new FDA‑approved therapy for fibromyalgia in more than 15 years when regulators cleared it on August 15, 2025, based on two pivotal Phase 3 trials involving nearly 1,000 patients.Tonix
17 November 2025
·
1 2 3

Stock Market Today

Northern Star Resources share price dips into weekend as $50m Central Tanami deal closes

Northern Star Resources share price dips into weekend as $50m Central Tanami deal closes

7 February 2026
Northern Star Resources fell 1.7% to A$26.77 Friday, extending losses as gold miners and the broader market declined. MGX Resources completed its A$50 million purchase of a 50% stake in the Central Tanami Gold Project from Northern Star. The All Ordinaries Gold index dropped 3.24%. CME Group raised COMEX gold futures margin requirements to 9% amid volatility.
PLS Group share price slips into weekend as Morgan Stanley and MUFG filings land

PLS Group share price slips into weekend as Morgan Stanley and MUFG filings land

7 February 2026
PLS Group shares closed at A$4.12 Friday, down 1.2% after a 3.7% drop Thursday. Morgan Stanley and Mitsubishi UFJ Financial Group disclosed increased voting power in the lithium miner, both citing changes dated Feb. 2. The moves came as lithium prices fell and Australian equities posted their sharpest drop in months. PLS reports interim results Feb. 19.
Commonwealth Bank share price near A$159 as CBA earnings, dividend week looms after ASX rout

Commonwealth Bank share price near A$159 as CBA earnings, dividend week looms after ASX rout

7 February 2026
Commonwealth Bank of Australia shares closed at A$158.91, down 0.23% Friday, as the S&P/ASX 200 fell 2.03% and nearly A$70 billion was wiped from the market. The bank reports half-year results and an interim dividend on Feb. 11, with shares going ex-dividend Feb. 18. CBA flagged a A$68 million provision linked to ASIC’s Better Banking review. The RBA raised rates to 3.85% on Feb. 3, with CBA passing on the increase from Feb. 13.
Go toTop